Chongqing Medical University

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Vendredi, avril 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

New Studies in Journal of Pharmaceutical Analysis Demonstrate Advancements in Nanotechnology and Their Impact Across Multiple Areas of Human Health

Retrieved on: 
Vendredi, avril 8, 2022
Journal, Diagnosis, Chongqing Normal University, Nanotechnology, Anhui University of Chinese Medicine, Research, Color, Nanoparticle, Chongqing Medical University, Cancer, Medicine, Neoplasm, Carbon, Car, Lanzhou University, DSDS, Medical device, Pharmaceutical industry

XI'AN, China, April 8, 2022 /PRNewswire/ -- Nanotechnology research has found applications in many fields, from medicine and drug research to aeronautics and automobiles. As a global leader in nanotechnology research, China has made valuable contributions to this field. These contributions have been further emphasized by a series of recent studies from Chinese researchers, which were published in the Journal of Pharmaceutical Analysis.

Key Points: 
  • As a global leader in nanotechnology research, China has made valuable contributions to this field.
  • These contributions have been further emphasized by a series of recent studies from Chinese researchers, which were published in the Journal of Pharmaceutical Analysis.
  • They also represent a new avenue for the non-pharmacological application of traditional Chinese medicines and could help prevent serious health problems."
  • In summary, nanotechnology acts at the intersection of various research fields and can and can revolutionize how we prevent, diagnose, and treat health conditions.

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

Retrieved on: 
Vendredi, septembre 17, 2021
People, WebRTC, Degenerative disease, Wu Zhongchao, Efficiency, Technology, Hematology, Forward-looking statement, MDT, Coronavirus, First Affiliated Hospital of Xinjiang Medical University, Patient, Company, Private Securities Litigation Reform Act, Microbiology, Second Affiliated Hospital of Xinjiang Medical University, Disease, Human, Physician, Infection, Medicine in China, Hospital, NASDAQ, Solution, Growth, Chinese Medical Doctor Association, Neoplasm, Review, Learning, Lists of diseases, Guangzhou Medical University, Diagnosis, Goal, SEC, Cancer, 301 Hospital, Chongqing Medical University, Ruijin Hospital, Medicine, Public relations

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").

Key Points: 
  • SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), aninternet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced the launch of its multidisciplinary treatment ("MDT") clinical thinking training platform for hematology ("Hematology MDT Platform").
  • The Hematology MDT Platform provides clinicians with a channel to learn multidisciplinary thinking skills online, in order to improve diagnosis and treatment and further the efficiency of treatment.
  • In addition, physicians can watch MDT training videos to learn the clinical thinking skills from experts and improve their problem-solving ability during the disease diagnosis and treatment.
  • Zhongchao's Hematology MDT platform provides physicians with a convenient and rapid access to learn and exchange MDT practices and experiences andwill promote the development of hematology treatment models in China.